

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act 1934

Date of Report (Date of earliest event reported): August 31, 2005

Titan Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)

<u>Delaware</u> (State or Other Jurisdiction of Incorporation)	<u>0-27436</u> (Commission File Number)	<u>94-3171940</u> (IRS Employer Identification No.)
---	--	--

<u>400 Oyster Point Blvd., Suite 505, South San Francisco, CA</u> (Address of Principal Executive Offices)	<u>94080</u> (Zip Code)
---	----------------------------

Registrant's telephone number, including area code: 650-244-4990

(Former Name or Former Address, is Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 5.02. Departure of Directors or Principal Officers; Election of Directors, Appointment of Principal Officers.

On August 31, 2005, Dr. Joachim-Friedrich Kapp was appointed to serve on the Board of Directors (the "Board") of Titan Pharmaceuticals, Inc. (the "Company"). Mr. Kapp has not been appointed to serve on any of the Board's committees and is not currently expected to be appointed to any committees.

There were no arrangements or understandings between Mr. Kapp and any other persons pursuant to which Mr. Kapp was selected as a director. There are no family relationships between or among Mr. Kapp and any executive officers or directors of the Company. Mr. Kapp is an executive officer of Schering AG, a corporate partner of the Company with respect to Titan's drug Spheramine. Other than the reimbursement of certain payments made by the Company on Schering's behalf, the Company did not receive any payments from Schering during the current year or in fiscal years 2004 and 2003.

Dr. Kapp was appointed to the Board to fill the vacancy created by the retirement of Dr. Ernst Afting on August 31, 2005. Dr. Afting will continue to work with Titan as a consultant. Dr. Afting's retirement from the Board was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

Item 9.01. Financial Statements and Exhibits.

Exhibits

Exhibit	Description
99.1	Press Release dated September 1, 2005

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TITAN PHARMACEUTICALS, INC.

Date: September 6, 2005

By: /s/ Robert E. Farrell

Robert E. Farrell
Chief Financial Officer

Exhibit Index

Exhibit	Description
99.1	Press Release dated September 1, 2005



Titan Pharmaceuticals, Inc.

Company:
Robert Farrell
Executive Vice President & CFO
650-244-4990

Media/Investors:
Jonathan Fassberg
The Trout Group
212-477-9077

FOR IMMEDIATE RELEASE

TITAN PHARMACEUTICALS APPOINTS DR. JOACHIM-FRIEDRICH KAPP TO ITS BOARD OF DIRECTORS

South San Francisco, CA - September 1, 2005 - Titan Pharmaceuticals, Inc. (AMEX: TTP) today announced that Dr. Joachim-Friedrich Kapp has been appointed to the Company's Board of Directors. Dr. Kapp is currently President, Global Business Unit Specialized Therapeutics, at Schering AG, Germany. Schering AG is Titan's corporate partner for the development of Spheramine®.

"We are delighted to add Dr. Kapp to our Board of Directors," stated Dr. Louis R. Bucalo, Chairman, President and CEO of Titan. "We believe that Dr. Kapp's expertise and experience in pharmaceutical development will be a valuable additional asset to Titan."

From 1975-1983, Dr. Kapp held positions of increasing responsibility at both Schering AG and its U.S. subsidiary Berlex, eventually being named in 1983 as Head of Schering AG's Cardiovascular Segment Management. In 1984, Dr. Kapp joined Gödecke AG, a subsidiary of Warner-Lambert, where he ultimately became Head of Research and Development, as well as Vice President and Head, International Clinical Development for Warner-Lambert. In 1991, Dr. Kapp returned to Schering AG where he thereafter was appointed President, GBU Specialized Therapeutics.

Concurrent with Dr. Kapp's appointment to the Board, Dr. Ernst Afting will be retiring from Titan's Board of Directors. Dr. Afting will continue to work with Titan as a consultant to the company.

“I am very pleased to join Titan’s Board of Directors,” said Dr. Kapp. “Titan is an innovative Company with several products in clinical testing. I look forward to working with the Company as it advances its development programs.”

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc. (AMEX: TTP) is a biopharmaceutical company focused on the development and commercialization of novel treatments for central nervous system disorders, cardiovascular disease, bone disease and other disorders. Titan's products in development utilize novel technologies that have the potential to significantly improve the treatment of these diseases. Titan also establishes partnerships with government institutions and other leading pharmaceutical development companies. For more information, please visit the Company’s website at www.titanpharm.com

The press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company's development program and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates that could slow or prevent product development or commercialization, the uncertainty of patent protection for the Company's intellectual property or trade secrets and the Company's ability to obtain additional financing if necessary. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release.

###